
Climb Bio rose 428.7% from $1.88 to $9.94, ahead of the S&P 500's +11.2%. Its worst day was Oct 26 (−13.5%), and its low came Nov 21 at $1.70.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Climb Bio closed at its lowest level of the year, 9.6% below where the year started.
−1.7% · S&P 500 +1.0%
Climb Bio shares rose 30.4%, while the S&P 500 fell 1.1%.
+30.4%, the year's best day · S&P 500 −1.1%
Story events cover the past 12 months · Times ET
Climb Bio shares rose 17.0%, while the S&P 500 rose 1.9%.
+17.0% · S&P 500 +1.9%
EPS of $-0.26 missed the $-0.20 estimate on $0.00 revenue.
+1.5% · S&P 500 −0.6%
EPS of $-0.20 beat the $-0.30 estimate on $0.00 revenue.
−2.5% · S&P 500 −0.3%
EPS of $-0.18 beat the $-0.22 estimate on $0.00 revenue.
+12.3% · S&P 500 −0.2%
Climb Bio closed at its highest level of the year, 848.9% above where the year started.
+8.8% · S&P 500 +0.3%
EPS of $-0.18 beat the $-0.20 estimate on $0.00 revenue.
−4.9% · S&P 500 −4.4%
Where it ended: a close of $9.94 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.19).
Nothing in the past 12 months.
All CLYM dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CLYM and SPY from Benzinga historical bars. Not investment advice.